Search

Your search keyword '"Francesco Biaduzzini"' showing total 7 results
Start Over Author "Francesco Biaduzzini"
7 results on '"Francesco Biaduzzini"'

1. Effects of Anti-CGRP Monoclonal Antibodies on Neurophysiological and Clinical Outcomes: A Combined Transcranial Magnetic Stimulation and Algometer Study

Author

Paolo Manganotti, Manuela Deodato, Laura D’Acunto, Francesco Biaduzzini, Gabriele Garascia, and Antonio Granato

Subjects
migraine, cortical excitability, anti-CGRP monoclonal antibodies, transcranial magnetic stimulation, motor cortex, trigeminocervical complex, Medicine, Internal medicine, RC31-1245, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Background: the aim of this study was to investigate the neurophysiological effect of anti-CGRP monoclonal antibodies on central and peripheral levels in migraine patients. Methods: An observational cohort study in patients with migraine was performed. All subjects underwent Single-Pulse and Paired-Pulse Transcranial Magnetic Stimulation, as well as a Pressure Pain Threshold assessment. The same protocol was repeated three and four months after the first injection of anti-CGRP monoclonal antibodies. Results: A total of 11 patients with a diagnosis of migraine and 11 healthy controls were enrolled. The main findings of this study are the significant effects of anti-CGRP mAb treatment on the TMS parameters of intracortical inhibition and the rise in the resting motor threshold in our group of patients affected by resistant migraine. The clinical effect of therapy on migraine is associated with the increase in short-interval intracortical inhibition (SICI), resting motor threshold (RMT), and Pressure Pain Threshold (PPT). In all patients, all clinical headache parameters improved significantly 3 months after the first injection of mAbs and the improvement was maintained at the 1-month follow-up. At baseline, migraineurs and HCs had significant differences in all TMS parameters and in PPT, while at follow-up assessment, no differences were observed on RMT, SICI, and PPT between the two groups. After anti-CGRP monoclonal antibody injection, a significant increase in the intracortical inhibition, in the motor threshold, and in the Pressure Pain Threshold in critical head areas was observed in patients with migraine, which was related to significant clinical benefits. Conclusions: Anti-CGRP monoclonal antibodies improved clinical and neurophysiological outcomes, reflecting a normalization of cortical excitability and peripheral and central sensitization. By directly acting on the thalamus or hypothalamus and indirectly on the trigeminocervical complex, treatment with anti-CGRP monoclonal antibodies may modulate central sensorimotor excitability and peripheral sensitization pain.

Published
2024
Full Text
View/download PDF

2. Cognitive deficit in post-acute COVID-19: an opportunity for EEG evaluation?

Author

Giovanni Furlanis, Alex Buoite Stella, Francesco Biaduzzini, Giulia Bellavita, Nicolò Arjuna Frezza, Sasha Olivo, Alina Menichelli, Alberta Lunardelli, Miloš Ajčević, Paolo Manganotti, Furlanis, Giovanni, Buoite Stella, Alex, Biaduzzini, Francesco, Bellavita, Giulia, Frezza, Nicolò Arjuna, Olivo, Sasha, Menichelli, Alina, Lunardelli, Alberta, Ajcevic, M, and Manganotti, Paolo

Subjects
Psychiatry and Mental health, Cognitive impairment, Post-COVID-19, COVID-19, EEG, Neurology (clinical), Dermatology, General Medicine
Abstract

Background and purpose: Among the most common post-COVID symptoms, many patients experienced subjective cognitive deficit, commonly named "brain fog," that might be present also in those individuals without severe acute COVID-19 respiratory involvement. Some studies have investigated some of the mechanisms that might be associated with the brain fog with objective techniques including transcranial magnetic stimulation and neuroimaging. Methods: The aim of this study was to investigate the presence of electroencephalographic (EEG) alterations in people with post-COVID self-reported cognitive deficit. Results: Out of the 90 patients attending the post-COVID neurology ambulatory service, twenty patients presenting brain fog at least 4 weeks after acute non-severe COVID-19 infection, and without previous history of epilepsy, were investigated with 19-channel EEG, Montreal Cognitive Assessment (MoCA), and magnetic resonance imaging (MRI). EEG was found altered in 65% of the sample, among which 69% presented a slowing activity and 31% were characterized by epileptic discharges principally in the frontal areas. None of the patients showed DWI MRI lesions. Conclusions: These findings highlight the usefulness of EEG analysis to objectively describe possible neurophysiological abnormalities in post-COVID patients presenting subjective cognitive deficit.

Published
2023

3. Combining perampanel and ketamine in super refractory post-traumatic status epilepticus: a case report

Author

Francesco Biaduzzini, Alessandro Dinoto, Stefano Meletti, Marta Cheli, Paolo Manganotti, Erik Roman-Pognuz, Giulia Mazzon, Marinella Tomaselli, Manganotti, P., Cheli, M., Dinoto, A., Biaduzzini, F., Tomaselli, M., Mazzon, G., Roman-Pognuz, E., and Meletti, S.

Subjects
ketamine, super refractory, Pyridones, Status epilepticus, Pyridone, perampanel, Perampanel, chemistry.chemical_compound, Epilepsy, Status Epilepticus, Nitriles, Anticonvulsant, medicine, Humans, Ketamine, Anticonvulsants, business.industry, Status epilepticu, General Medicine, medicine.disease, Neurology, chemistry, Anesthesia, Neurology (clinical), medicine.symptom, business, Nitrile, Super refractory, Human, medicine.drug
Abstract

Status Epilepticus (SE) is a condition resulting either from the failure of seizure termination mechanisms or from the abnormal activation of prolonged seizure mechanisms. It represents a life-threatening medical emergency associated with high morbidity and mortality that requires prompt diagnosis and treatment. SE treatment begins with a quick-acting benzodiazepine, followed by intravenous (IV) loading and a continuous infusion of antiseizure medications (ASMs). The failure of first- and second-line treatments is defined as “refractory SE” (RSE) and requires infusion of IV anaesthetics. If anaesthetics fail or SE recurs after 24 hours, SE is defined as “super refractory status epilepticus” (SRSE).

Published
2021

4. Clinical variability and the role of diagnostic criteria of cerebral amyloid angiopathy-related inflammation (CAA-RI): A case series

Author

Francesco Biaduzzini, Alessio Bratina, Fulvio Pasquin, Paolo Manganotti, Arianna Sartori, Laura D’Acunto, Alessandro Dinoto, and Valentina Tommasini

Subjects
Pathology, medicine.medical_specialty, Neurology, business.industry, medicine, Inflammation, Neurology (clinical), Cerebral amyloid angiopathy, medicine.symptom, medicine.disease, business
Published
2021

5. Connected speech deficit as an early hallmark of CSF-defined Alzheimer's disease and correlation with cerebral hypoperfusion pattern

Author

Franca Dore, Alina Menichelli, Tatiana Cattaruzza, Paolo Manganotti, Valentina Pesavento, Sandro Sorbi, Michele Guerriero, Miloš Ajčević, Francesco Biaduzzini, Andrea Marini, Selene Capitanio, and Giulia Mazzon

Subjects
Correlation, medicine.medical_specialty, Neurology, Cerebral hypoperfusion, business.industry, Internal medicine, Cardiology, Medicine, Neurology (clinical), Disease, business, Connected speech
Published
2021

6. Super refractory post-traumatic status epilepticus treated with combining perampanel and ketamine

Author

Paolo Manganotti, Stefano Meletti, Erik Roman-Pognuz, Giulia Mazzon, Alessandro Dinoto, Marta Cheli, Francesco Biaduzzini, and Marinella Tomaselli

Subjects
business.industry, Status epilepticus, Perampanel, chemistry.chemical_compound, Neurology, chemistry, Anesthesia, Medicine, Ketamine, Neurology (clinical), medicine.symptom, business, Super refractory, medicine.drug
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results